Dermatological adverse effects of anti‐glaucoma eye drops: a review

2022 ◽  
Author(s):  
Alexandra Patchinsky ◽  
Nadine Petitpain ◽  
Pierre Gillet ◽  
Karine Angioi‐Duprez ◽  
Jean Luc Schmutz ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Eye Drops

A Survey of Neonatal Nurses on Mydriatic Regimens Used in Neonatal Retinopathy of Prematurity Eye Examinations

2021 ◽  
Author(s):  
Lisa Kremer ◽  
David Reith ◽  
Natalie J. Medlicott ◽  
Mary J. Sime ◽  
Liza Edmonds ◽  
...  
Keyword(s):  
New Zealand ◽  
Adverse Effects ◽  
Retinopathy Of Prematurity ◽  
Adverse Drug Events ◽  
Preterm Neonates ◽  
Eye Drops ◽  
Cross Sectional Survey ◽  
Cross Sectional ◽  
Aotearoa New Zealand ◽  
Adult Dose

Objective This study was aimed to determine mydriatic regimen(s) used in neonatal units in Aotearoa New Zealand (NZ) and Australia and to estimate the frequency of adverse drug events following mydriatic administration in preterm neonates. Study Design A cross-sectional survey was sent to neonatal nursing staff listed in the Australian and New Zealand Neonatal Network contact list. Participants were asked to state what mydriatic regimen they use, and to estimate the frequency of adverse drug events when eye drops were administered for retinopathy of prematurity eye examinations (ROPEE). Results Thirteen different mydriatic regimens were identified; phenylephrine 2.5% and cyclopentolate 0.5% (1 standard drop of each) was the most commonly used regimen. Two of the regimens exceeded adult doses and five regimens included a mydriatic that is equivalent to an adult dose. Following mydriatic instillation, the three most common adverse effects were apnea, tachycardia, and periorbital pallor. Conclusion Low-concentration single-microdrop regimens are currently in use and resulting in successful ROPEE, yet doses exceeding adult doses are in use throughout Aotearoa NZ and Australian units. We know from this dataset that neonates are experiencing unwanted and potentially preventable, adverse effects associated with mydriatics, and every effort should be made to minimize this risk. Key Points

E

2020 ◽  
pp. 275-307
Author(s):  
Sean Ainsworth
Keyword(s):  
Adverse Effects ◽  
Enzyme Replacement Therapy ◽  
Replacement Therapy ◽  
Recombinant Human Erythropoietin ◽  
Eye Drops ◽  
Enzyme Replacement ◽  
Maternal Treatment ◽  
Human Erythropoietin

This chapter presents information on neonatal drugs that begin with E, including use, pharmacology, adverse effects, fetal and infant implications of maternal treatment, treatment, and supply of Enemas, laxatives, and suppositories, Enoxaparin, Enzyme replacement therapy, Epoetin (recombinant human erythropoietin = rEPO), Epoprostenol and other prostanoids (iloprost and teoprostinil), Erythromycin, Esomeprazole, Ethambutol, and Eye drops (and ointments)

Managing Primary Open-angle Glaucoma – Ocular Tolerability, Compliance, Persistence and Patient Outcomes

2009 ◽  
Vol 03 (01) ◽  
pp. 19 ◽  
Author(s):  
Anton Hommer ◽  
Keyword(s):  
Adverse Effects ◽  
Patient Compliance ◽  
Vision Loss ◽  
Primary Open Angle Glaucoma ◽  
Open Angle Glaucoma ◽  
Tolerability Profile ◽  
Eye Drops ◽  
Open Angle ◽  
The Individual ◽  
Ocular Tolerability

Primary open-angle glaucoma (POAG) is a progressive optic neuropathy that, left untreated, can lead to irreversible damage to the optic nerve and permanent vision loss. To date, intraocular pressure (IOP) is the only modifiable risk factor for disease progression, and topical eye-drops are currently used as the leading non-surgical glaucoma therapy. Despite the efficacy of pharmacotherapy in lowering IOP, success is ultimately defined by patient compliance and patient persistence. Ocular tolerability is a crucial factor in patient compliance and persistence; non-adherence owing to adverse effects can lead to poor control of IOP and treatment failure. Prostaglandin analogues are currently the first-line antiglaucoma agents, with a good tolerability profile and a better IOP-lowering effect compared with β-blockers. Combination therapies have also shown greater efficacy in lowering IOP compared with the individual constituents, with fewer adverse effects. Treatment should be tailored to the individual patient, with a focus on ocular tolerability and its role in adherence, compliance and vision preservation.

scholarly journals Acute red eye following the use of steroid eye drops by patients seen at the eye clinic, department of ophthalmology, Chukwuemeka Odumegwu Ojukwu University Teaching Hospital Amaku – Awka, South Eastern Nigeria: Case series

2021 ◽  
Vol 2 (1) ◽  
pp. 01-07
Author(s):  
Ochiogu Bernard Chukwunonyerem ◽  
Udeaja Anthonia Chinyelu ◽  
Ughachukwu Peter Olisa
Keyword(s):  
Adverse Effects ◽  
Topical Steroid ◽  
Case Series ◽  
University Teaching ◽  
Eye Drops ◽  
Steroid Use ◽  
Important Group ◽  
Red Eye ◽  
Department Of Ophthalmology ◽  
Eye Clinic

Five cases (one male, four females aged between 32-65 years) of acute painful red eye following application of steroid eye drops have been presented. Their presentation followed a similar trend viz: sudden painful eyes, redness, tearing, photophobia, tenderness, and blepharospasm following topical steroid eye use. There was immediate relief within an hour of instillation of atropine 1% eye drop and full recovery after two weeks of presentation following further treatment with atropine 1% eye drop, tablet paracetamol, chloramphenicol eye drop and flurbiprofen eye drop. Steroids are important group of drugs that are employed in the management of many medical conditions. When used properly, they bring good results most of the time. Acute red eye was observed in this case series following topical steroid use on the eyes and the patients need to be educated on the proper use of this group of drugs so as to reduce its adverse effects.

Prostaglandin analogues: A double-edged sword in orbital glaucoma disease management

2020 ◽  
pp. 112067212090529
Author(s):  
Varajini Joganathan ◽  
Paul S Cannon ◽  
Karl Mercieca
Keyword(s):  
Intraocular Pressure ◽  
Adverse Effects ◽  
Ocular Hypertension ◽  
Pressure Rise ◽  
Eye Drops ◽  
Prostaglandin Analogue ◽  
Prostaglandin Analogues ◽  
Patient Reported ◽  
The Aesthetic ◽  
Orbital Disease

Introduction: The authors describe benefits of the recognised adverse effects of prostaglandin analogues on periocular structures in patients with unilateral proptosis and intraocular pressure rise. This case points to intentional consideration of prostaglandin analogue therapy in this selected cohort of patients with secondary ocular hypertension and proptosis. Case description: A 70-year-old gentleman who presented with a 1-week history of a red and painful right eye associated with tortuous and dilated episcleral blood vessels. Visual acuity was unaffected. A diagnosis of idiopathic orbital inflammatory disease was made by extraocular muscle biopsy. Two weeks later, the patient presented with worsening pain, reduced vision and raised intraocular pressure. The secondary ocular hypertension was successfully treated with topical preserved eye drops, including latanoprost, a prostaglandin analogue. Over 6 months, the patient developed drop intolerance and punctate keratopathy leading to therapy non-adherence. Interestingly, the patient reported improvement in periocular appearance related to prostaglandin-associated periorbitopathy. Ocular surface disease and intraocular pressures were subsequently managed with preservative-free eye drops. Conclusion: Secondary ocular hypertension is not an uncommon consequence of orbital disease. Prostaglandin analogue can act as a double-edged sword in the management of raised intraocular pressure by reducing eye pressure at the cost of developing adverse effects of prostaglandin-associated periorbitopathy. These adverse effects however can be beneficial in the aesthetic rehabilitation of proptosis and associated exposure keratopathy in patients with unilateral orbital disease and probably should be sought as first line treatment in those with proptosis and raised intraocular pressure.

scholarly journals A multicenter Spanish study of atropine 0.01% in childhood myopia progression

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Inés Pérez-Flores ◽  
Beatríz Macías-Murelaga ◽  
Jesús Barrio-Barrio ◽  
Inés Pérez Flores ◽  
Marta Valcárcel Vizcaíno ◽  
...  
Keyword(s):  
Risk Factors ◽  
Adverse Effects ◽  
Pupil Diameter ◽  
Pediatric Population ◽  
Anterior Chamber Depth ◽  
Eye Drops ◽  
Myopia Progression ◽  
Telephone Consultation ◽  
Progression Risk

AbstractTo evaluate the efficacy and safety of atropine 0.01% eye drops for myopia control in a multicentric pediatric Spanish cohort. An interventional, prospective, multicenter study was designed. Children aged between 6 and 14 years, with myopia between − 2.00 D to − 6.00 D, astigmatism < 1.50 D and documented previous annual progression greater than − 0.5 D (cycloplegic spherical equivalent, SE) were included. Once nightly atropine 0.01% eye drops in each eye were prescribed to all participants for 12 months. Age, gender, ethnicity and iris color were registered. All patients underwent the same follow-up protocol in every center: baseline visit, telephone consultation 2 weeks later and office controls at 4, 8 and 12 months. At each visit, best-corrected visual acuity, and cycloplegic autorefraction were assessed. Axial length (AL), anterior chamber depth and pupil diameter were measured on an IOL Master (Carl Zeiss Meditec, Inc, Dublin, CA). Adverse effects were registered in a specific questionnaire. Mean changes in cycloplegic SE and AL in the 12 months follow-up were analyzed. SE progression during treatment was compared with the SE progression in the year before enrollment for each patient. Correlation between SE and AL, and annual progression distribution were evaluated. Progression risk factors were analyzed by multivariate logistic regression analyses. Of the 105 recruited children, 92 completed the treatment. Mean SE and AL changes were − 0.44 ± 0.41 D and 0.27 ± 0.20 mm respectively. Mean SE progression was lower than the year before treatment (− 0.44 ± 0.41 D versus − 1.01 ± 0.38 D; p < 0.0001). An inverse correlation between SE progression and AL progression (r: − 0.42; p < 0.0001) was found. Fifty-seven patients (62%) had a SE progression less than − 0.50 D. No risk factors associated with progression could be identified in multivariate analyses. Mean pupil diameter increment at 12-months visit was 0.74 ± 1.76 mm. The adverse effects were mild and infrequent, and decreased over the time. Atropine 0.01% is effective and safe for myopia progression control in a multicentric Spanish children cohort. We believe this efficacy might be extensible to the myopic pediatric population from Western countries with similar social and demographic features. More studies about myopia progression risk factors among atropine treated patients are needed.

scholarly journals A Single Drop in the Eye – Effects on the Whole Body?

2017 ◽  
Vol 11 (1) ◽  
pp. 305-314 ◽  
Author(s):  
Anu Vaajanen ◽  
Heikki Vapaatalo
Keyword(s):  
Adverse Effects ◽  
Whole Body ◽  
Systemic Absorption ◽  
Eye Drops ◽  
Allergic Reactions ◽  
Single Drop ◽  
Active Components ◽  
Life Threatening ◽  
Systemic Side Effects ◽  
Kinetics Of

Introduction: Although the local adverse effects of ophthalmic drugs, including allergic reactions, are well recognized, less is known about the systemic side- effects of eye drops, especially during pregnancy, breast-feeding and early childhood. Ophthalmologists should also be aware of unusual, in some cases even life-threatening, effects of commonly used eye drops. Conclusion: This brief review outlines the routes of systemic absorption and the kinetics of active components present in eye drops, and identifies the clinically relevant systemic adverse effects.

AYURVEDIC APPROACH OF ALLERGIC CONJUNCTIVITIS (VATAJA ABHISHYANDA)

2021 ◽  
Vol 9 (5) ◽  
pp. 988-994
Author(s):  
Manisha Rajput ◽  
Sukhdev Singh ◽  
Sanjeev Kumar Sharma ◽  
Yogitha Bali M.R
Keyword(s):  
Adverse Effects ◽  
Allergic Conjunctivitis ◽  
Age Groups ◽  
Modern Medicine ◽  
Ayurvedic Medicine ◽  
Eye Drops ◽  
Root Cause ◽  
Effective Interventions ◽  
Eye Disorders ◽  
Chronic Course

Allergic conjunctivitis is one of the most common eye disorders that affect people of all age groups and can be correlated to Vatajaabhishyanda (Allerghic Conjunctivitis) in Ayurvedic medicine based on their signs and symp- toms. Abhishyanda (Conjunctivitis) is the root cause for most of the eye disorders and must be treated early with effective interventions or it might lead to severe complications and would be very perplexing to save the eyesight. If Abhishyanda (Conjunctivitis) takes a chronic course, it may lead to dreadful complications making the disease unmanageable. In Modern medicine, this is managed with the administration of eye drops and anti-Allergic medi- cines associated that are associated with some adverse effects. Ayurvedic management of Allergic conjunctivitis has shown some effective results in overcoming the ailment with no such effects and non-recurrence. Hence here an effort has been made to elucidate about Vatajaabhishyanda and its management that is outlined in Ayurvedic classics. Keywords: Vatajaabhishyanda, Allergic conjunctivitis, Ayurveda, Shalakya Tantra

Paroxetine Markedly Increases Plasma Concentrations of Ophthalmic Timolol; CYP2D6 Inhibitors May Increase the Risk of Cardiovascular Adverse Effects of 0.5% Timolol Eye Drops

2014 ◽  
Vol 42 (12) ◽  
pp. 2068-2076 ◽  
Author(s):  
Jukka Mäenpää ◽  
Marjo Volotinen-Maja ◽  
Hannu Kautiainen ◽  
Mikko Neuvonen ◽  
Mikko Niemi ◽  
...  
Keyword(s):  
Adverse Effects ◽  
Plasma Concentrations ◽  
Eye Drops ◽  
Cyp2d6 Inhibitors
Sign in / Sign up

Export Citation Format

Share Document